Obesity Clinical Trial
Official title:
Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy
Verified date | May 2018 |
Source | MetroHealth Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized, double-blind placebo controlled trial of fish oil to decrease inflammation in pregnancy.
Status | Completed |
Enrollment | 72 |
Est. completion date | June 2013 |
Est. primary completion date | March 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - BMI (wt/ht2) > or = 25 at first antenatal visit - Gestational age at randomization between 8-16 weeks - No medical problems such as hyperlipidemia, hypertension, or pregestational diabetes - Between the ages of 18 and 40 years old - Non-smokers - No obstetrical problems such as a history of preeclampsia or gestational diabetes - Confirmed singleton pregnancy Exclusion Criteria: - Major fetal anomaly - Regular intake of fish oil supplements (defined as greater than 500 mg per week within the last four weeks). This is due to the placebo group receiving fish oil outside of the study. - Daily use of nonsteroidal anti-inflammatory agents - Allergy to fish or fish products, gluten intolerant (because the placebo contains wheat germ oil, which is not gluten free). - Women who are vegetarians and do not eat any fish. - Infants born preterm (less than 36 weeks gestation) or less than 2kg. - Heparin use or known thrombophilia (thrombophilias include homozygous for Factor V Leiden). - Moderate or high titer IgG anticardiolipin antibodies or prolonged activated PTT or other indication of presence of lupus anticoagulant, homozygous for prothrombin gene (G20210A) mutation, antithrombin III deficiency. - Protein S (low levels outside of pregnancy) or Protein C deficiency. - Hyperhomocysteinemia (due to safety concerns because n-3 may affect bleeding time). - Hemophiliacs including von Willebrand's disease (because of safety concerns associated with the hemophilia treatment combined with the n-3 supplements). - Planned termination of pregnancy. - Current hypertension or current use of antihypertensive medication (including diuretics), due to increased risk of adverse pregnancy outcome. - Pregestational diabetes due to increased risks of affecting fetal growth. We will not exclude women who develop GDM during pregnancy but consider a sub-analyses of these women depending on the number of subjects. Known maternal medical complications: cancer (including melanoma but excluding other skin cancers). - Current hyperthyroidism if not adequately controlled. - Renal disease with altered renal function (serum creatinine > 1.5). - Epilepsy or other seizure disorder. - Systemic lupus (not discoid lupus), scleroderma, polymyalgia rheumatic. - Active liver disease (acute hepatitis, chronic active hepatitis, persistently abnormal liver enzymes). - Platelet or red blood cell disorder (including idiopathic thrombocytopenia purpura, a history of alloimmune thrombocytopenia in a previous offspring, significant anemia due to hemoglobinopathy but not sickle cell trait. Iron deficiency anemia will NOT be an exclusion as long as the hemoglobin is > 8 gm/dl). - Chronic pulmonary disease (asthma of any degree of severity is NOT an exclusion). - Structural, functional or ischemic heart disease. Neither mitral valve prolapse nor paroxysmal supraventricular tachycardia are considered exclusions. - Known HIV positive with viral load greater than 1,000 copies/ml or CD4 count less than 350/mm3. - Current or planned cerclage due to interference with the natural cause of delivery. - Illicit drug or alcohol abuse during current pregnancy. - At the time of birth, all infants will be evaluated by a pediatrician to make sure that they are healthy. Infants will be excluded from further study if they have any medical problems such as respiratory distress syndrome. - Infants will also be excluded if they have any problems that exclude them from having estimation of body composition, for e.g. birth weight less than 2 kg. |
Country | Name | City | State |
---|---|---|---|
United States | MetroHealth Medical Center | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
MetroHealth Medical Center | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Decreased inflammation during human pregnancy | cytokine concentration in plasma, placenta and white adipose tissue | enrollment (8-16 weeks) to delivery | |
Secondary | Reduction of insulin resistance | insulin sensitivity as estimated by OGTT | enrollment (8-16 weeks) to delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |